Plasma Prolactin in Schizophrenia Subjects Treated with Seroquel™ (ICI 204,636)

Psychopharmacology Bulletin

Volumn 32, Issue 1, 1996, Pages 107-110

  Hamner, Mark B ^a   Arvanitis, Lisa A ^b   Miller, Barbara G ^b   Link, Christopher G G ^b   Hong, Walter W ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Antipsychotic; Extrapyramidal; Outcome; Prolactin; Schizophrenia

Indexed keywords

CHLORPROMAZINE; PLACEBO; PROLACTIN; QUETIAPINE;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PROLACTIN; SCHIZOPHRENIA; TIME FACTORS;

EID: 0030013802     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. American Psychiatric Association. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders. 3d ed., revised. Washington, DC: The Association, 1987.
2. Baldessarini, RJ, and Frankenburn, FR. Clozapine. A novel antipsychotic agent. N. Engl. J. Med. 324:746-754, 1991.
3. Ereshefsky, L; Watanabe, MD; and Tran-Johnson, TK. Clozapine: An atypical antipsychotic agent. Clin. Pharm. 8:691-709, 1989.
4. Goldstein, JM; Litwin, LC; Sutton, EB; and Malick, JB. Seroquel: Electrophysiological profile of a potential antipsychotic. Psychopharmacology 112:293-298, 1993.
5. Kay, SR; Fiszbein, A; and Opler, LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13(2):261-276, 1987.
6. Lieberman, JA; Safferman, AZ; Pollack, S; Szymanski, S; Johns, C; Howard, A; Kronig, M; Bookstein, P; and Kane, JM. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. Am. J. Psychiatry 151(12):1744-1752, 1994.
7. Meltzer, HY, and Fang, VS. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch. Gen. Psychiatry 33:279-286, 1976.
8. Migler, BM; Warawa, EJ; and Malick, JB. Seroquel: Behavioral effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology 112:299-307, 1993.
9. National Institute of Mental Health. Special feature: Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol. Bull. 21(4), 1985.
10. Newcomer, JW; Riney, SJ; Vinogradov, S; and Csernansky, JG. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia. Psychiatry Res. 41:191-202, 1992.
11. Overall, JE, and Gorham, DR. Introduction - The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol. Bull. 24:97-99, 1988.
12. Peabody, CA; Warner, MD; Griffin, M; Boutros, NN; Worsley, IG; and Friesen, HG. Prolactin bioassay in schizophrenia before and after neuroleptics. Psychiatry Res. 41:249-255, 1992.
13. Pickar, D. Prospects for pharmacotherapy of schizophrenia. Lancet 345(8949):557-562, 1995.
14. Saller, CF, and Salama, AL. Seroquel: Biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112:285-292, 1993.
15. Simpson, GM, and Angus, JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 212:11-19, 1970.